Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07103720 · ClinicalTrials.gov registry record · Phase 4
The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron
A Phase 4 study of Allergy, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07103720: Recruiting Phase 4 study of Allergy, sponsored by Mayo Clinic.
NCT07103720 is a Phase 4 study of Allergy that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 328-participant average among 15 other Allergy trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07103720, a Phase 4 study of Allergy, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Perioperative anaphylaxis is a potentially life-threatening drug allergic reaction that can occur during anesthetic procedures. The purpose of this research is to determine the maximal nonirritating skin testing concentrations of midazolam, ketamine and ondansetron. These drugs are FDA approved and commonly used before, during and after surgical procedures.
Primary Outcome
Determine the maximal nonirritating concentrations of midazolam, ketamine and ondansetron
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Skin Testing
Study Locations (1)
Arizona
- Mayo Clinic Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2026-10-30 |
| Phase | Phase 4 |
What NCT07103720 shows while recruiting
NCT07103720 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 328-participant average among 15 other Allergy trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Allergy appearing as the primary indexed condition, and to 1 intervention - of which Skin Testing is the first listed.
NCT07103720 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT07103720 about?
NCT07103720 is a clinical study titled "The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron". Perioperative anaphylaxis is a potentially life-threatening drug allergic reaction that can occur during anesthetic procedures. The purpose of this research is to determine the maximal nonirritating skin testing concentrations of midazolam, ketamine and ondansetron. These drugs are FDA approved and ...
What is the current status of trial NCT07103720?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2025-11-05. Estimated completion is 2026-10-30.
What conditions does trial NCT07103720 study?
This clinical trial studies the following conditions: Allergy.
What interventions are being tested in trial NCT07103720?
The interventions under investigation include: Skin Testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07103720?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07103720 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07103720's enrollment target sits among peer trials
60 9th of 15 higher than 7 of 15 other Allergy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Understanding Allergies and Sensitizations in Healthy and Allergic Individuals
RECRUITING
-
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RECRUITING · Phase 3
-
Childhood Allergy and the Neonatal Environment
ACTIVE NOT RECRUITING
-
Urban Environmental Factors and Childhood Asthma
COMPLETED
-
Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies
COMPLETED · Phase 2
-
Vitamin D, Steroids, and Asthma in African American Youth
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI